Nitzan Rosenfeld

Nitzan Rosenfeld is a Professor and Senior Group Leader at the CRUK Cambridge Institute, University of Cambridge. He is one of the world's leading developers of circulating cell-free DNA (cfDNA) and ctDNA analytical technologies for cancer early detection and monitoring. Rosenfeld's laboratory has made key discoveries about the biological properties of cfDNA including nucleosome positioning patterns, DNA fragmentation size distributions, and methylation signatures that differ between cancer patients and healthy individuals. These insights enabled development of low-tumor-fraction detection methods. He was a co-founder and early scientific contributor to GRAIL (now Illumina GRAIL), the company developing the Galleri multi-cancer early detection blood test now in clinical trials and CE-marked in Europe. His work bridges fundamental cancer biology with clinical liquid biopsy technology.

Nitzan Rosenfeld 是剑桥大学英国癌症研究剑桥研究所的教授和高级研究组组长。他是液体活检（cfDNA/ctDNA）分析技术用于癌症早期检测和监测领域的世界顶级开发者之一。 Rosenfeld的实验室对cfDNA的生物学特性做出了关键发现，包括核小体定位模式、DNA片段化大小分布以及癌症患者与健康人之间不同的甲基化特征。这些发现推动了低肿瘤分数检测方法的开发。